Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 5 10 SULFITE FREE W ELECT IN DEXTROSE 10 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 5 10 SULFITE FREE W ELECT IN DEXTROSE 10 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 5 IN PLASTIC CONTAINER.
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLINIMIX E 5/10 provides essential amino acids, electrolytes, and dextrose for parenteral nutrition, supporting protein synthesis and energy metabolism. Dextrose supplies glucose for cellular energy, while amino acids serve as substrates for protein synthesis. Electrolytes maintain acid-base balance and osmotic regulation.
Travasol 4.25% in dextrose 5% is a parenteral nutrition solution providing amino acids and carbohydrates. Amino acids serve as substrates for protein synthesis and other metabolic processes, while dextrose provides a source of glucose for energy. The combination supports tissue repair, growth, and maintenance.
Intravenous infusion. Dosage is individualized based on patient's metabolic requirements, clinical condition, and laboratory parameters. Typical adult dose: 1.5-2 g amino acids/kg/day and 10-15 g dextrose/kg/day (max 5 mg/kg/min dextrose). Rate: Infuse via central line at ≤ 3 mL/kg/hr initially, titrate up to 100-125 mL/hr. Do not exceed 125 mL/hr.
Intravenous infusion: 500-2000 mL per day as a source of amino acids and calories, adjusted based on metabolic needs and clinical response. Typical adult dose is 1.5-2.0 g/kg/day of amino acids (equivalent to 35-47 mL/kg/day of TRAVASOL 4.25% IN DEXTROSE 5%) administered via central or peripheral line.
None Documented
None Documented
Amino acids: variable, ~1-2 hours for most, reflecting rapid metabolism and utilization. Dextrose: not applicable as endogenous molecule; infusion half-life ~15-30 minutes due to insulin-mediated clearance. Clinical context: renal impairment prolongs amino acid elimination.
Not applicable as a combined product; amino acids have half-lives of minutes to hours depending on individual amino acid, and dextrose has a half-life of ~15-20 minutes under normal glucose homeostasis.
Amino acids and electrolytes are primarily excreted renally. Dextrose is metabolized to CO2 and water, exhaled via lungs. Unmetabolized dextrose excreted renally if threshold exceeded. Less than 5% biliary/fecal.
Travasol 4.25% in dextrose 5% is a parenteral nutrition solution; the amino acids are metabolized and the nitrogen is excreted primarily in urine as urea (≥90%). Dextrose is metabolized to CO2 and water, with minimal biliary or fecal excretion.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution